Forward QI-Module 10: Metabolic and Bariatric Surgery

Video Transcription

Video Summary

Module 10 (2023 update) reviews metabolic and bariatric surgery as the most effective long-term intervention for severe obesity, yet it is used by only ~1% of eligible U.S. patients despite >260,000 annual procedures. The most common operation is vertical sleeve gastrectomy, followed by Roux-en-Y gastric bypass; adjustable gastric banding is now rare. Surgery is no longer viewed as purely “restrictive” or “malabsorptive.” Beyond reduced stomach volume, potential mechanisms include changes in gut hormones (e.g., lower ghrelin, higher GLP-1/PYY), bile acids, branched-chain amino acids, and the gut microbiome, producing both weight-dependent and weight-independent metabolic benefits (notably for type 2 diabetes). Outcomes include durable >15% weight loss at 10 years and reduced obesity-related complications, including lower major cardiovascular events, kidney benefits, and reduced hormone-related cancer risk.<br /><br />Updated 2022 ASMBS/IFSO guidance supports surgery for BMI ≥35 regardless of comorbidities, BMI ≥30 with type 2 diabetes, and lower thresholds for some Asian populations; adolescents with severe obesity may qualify. Pre-op care includes screening for mental health issues, OSA, cardiovascular/VTE risk, and micronutrient deficiencies; mandated pre-op weight loss is not evidence-based. Key procedure-specific issues include GERD after sleeve, ulcer risk with bypass (worse with smoking/NSAIDs), and lifelong micronutrient monitoring. Weight regain can occur; anti-obesity medications may help when response is inadequate or regain develops.

Keywords

metabolic and bariatric surgery

vertical sleeve gastrectomy

Roux-en-Y gastric bypass

gut hormones (GLP-1, PYY, ghrelin)

type 2 diabetes remission

ASMBS/IFSO 2022 guidelines

micronutrient monitoring and deficiencies